For me it is Joe's confidence in NGIO's valuation being "over the top" vs the previous valuation.
Now we have:
10 year data
Merck
Shenzen
New studies to start add value
I am also grateful we are still in the running for BARDA funds
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
-
-
-
-
-
-
-